Brought to you by 
Amgen scoops up Dezima for $300mm plus potential earn-outs of $1.25bn
30 Mar 2021
Executive Summary
Concurrent with signing a potential $1.75bn monoclonal antibody development deal with Xencor, Amgen Inc. is acquiring cardiovascular-focused start-up Dezima Pharma BV for $300mm in cash up front, up to $1.25bn in earn-outs based on development and sales achievements, and low single-digit royalties.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Cash for Equity
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Amgen scoops up Dezima for $300mm plus potential earn-outs of $1.25bn
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice